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INTRODUCTION
IgA nephropathy (IgAN) is the most frequent primary
glomerulonephritis that presents with hematuria and often
proteinuria. Although a moderate degree of proteinuria is
common in patients with IgAN, nephrotic syndrome is con-
sidered uncommon in these patients. Previous studies have
demonstrated that some cases of IgAN presenting with the
nephrotic syndrome responded to corticosteroid therapy.
However, the response to steroid treatment has been vari-
able, and usually correlated with the underlying histological
changes. Some have suggested that these IgAN patients
represent a variant type of IgAN (1-3); however, others have
proposed that these cases might be variant type of minimal
change disease (MCD), such as MCD with coincidental
mesangial IgA deposits (4-6). Recently, it has been postulat-
ed that mesangial IgA deposition in MCD might represent
the coincidental occurrence of MCD and IgAN (7).
We have treated several IgAN patients presenting with
nephrotic syndrome. Some of these patients responded well
to corticosteroid therapy, and they showed complete remis-
sion of the nephrotic syndrome. The others, however, did
not respond to steroid therapy, and they had progressive renal
deterioration. Since MCD is the most common cause of adult
nephrotic syndrome in Korea, we thought that the steroid-
responders might have concurrent MCD in addition to IgAN.
In the present study, we evaluated the clinical and patho-
logical features of patients with IgAN that presented with
steroid-responsive nephrotic syndrome. 
MATERIALS AND METHODS 
Patients
From 2001 to 2007, a total of 581 patients were diagnosed
with primary IgAN at the Seoul National University Hos-
pital, which accounted for 37.0% of all kidney biopsies. The
diagnosis of IgAN was based on immunofluorescence micro-
scopy showing mesangial IgA deposition as the predominant
or co-dominant immunoglobulin. Henoch-Scholein purpu-
ra, systemic lupus erythematosus and liver cirrhosis were
excluded by detailed clinical history, physical examination
and laboratory findings. Among 581 patients with IgAN,
48 patients (8.3%) presented with the nephrotic syndrome;
the nephrotic syndrome was defined by generalized edema,
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Clinicopathologic Characteristics of IgA Nephropathy with 
Steroid-responsive Nephrotic Syndrome
Nephrotic syndrome is an unusual manifestation of IgA Nephropathy (IgAN). Some
cases respond to steroid treatment. Here we describe a case-series of IgAN patients
with steroid-responsive nephrotic syndrome. Twelve patients with IgAN with steroid-
responsive nephrotic syndrome were evaluated and followed up. All patients pre-
sented with generalized edema. Renal insufficiency was found in two patients. The
renal biopsy of eight patients revealed wide foot process effacement in addition to
the typical features of IgAN. They showed complete remission after steroid thera-
py. Seven relapses were reported in five patients; six of the relapsed cases respond-
ed to steroid therapy. Compared with steroid-non-responsive patients, the patients
with steroid-responsive nephrotic syndrome had shorter symptom duration, more
weight gain, more proteinuria, and lower histologic grade than did those that had
steroid-non-responsive nephrotic syndrome at presentation. None of the respon-
ders progressed to end stage renal disease, whereas five (38%) non-responders
required dialysis or renal transplantation. Patients with IgAN who have steroid-respon-
sive nephrotic syndrome likely have both minimal change disease and IgAN. The
clinical features of sudden onset of generalized edema, initial heavy proteinuria
and initial severe hypoalbuminemia might help identify the subset of patients, espe-
cially in low grade IgAN. 
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heavy proteinuria of more than 3.5 g/day, hypoalbumine-
mia of less than 3.5 g/dL, and/or hypercholesterolemia of
more than 200 mg/dL. Twenty five patients received steroid
treatment, and a retrospective analysis revealed 12 patients
that had complete remission with high-dose steroid thera-
py. The following blood and urinary laboratory tests were
performed in all patients at varying intervals: serum creati-
nine, blood urea nitrogen, urine protein, and urinalysis. 
A reduction of proteinuria to less than 1.0 g/day was des-
ignated as a response, and the complete correction of the
biochemical findings including absence of proteinuria (less
than 0.3 g/day) was considered a complete remission. Relapse
of the nephrotic syndrome was defined as the recurrence of
significant proteinuria (more than 1.0 g/day) and edema.
Histology grading
The light microscopy features of the renal biopsy were
examined to evaluate the glomerular changes, which were
classified into grades I-V according to the disease severity as
described previously (8): grade I, normal or focal mesangial
cell proliferation; grade II, diffuse mesangial cell proliferation,
or <25% of glomeruli with crescent (Cr)/segmental sclero-
sis (SS)/global sclerosis (GS); grade III, 25-49% of glomeruli
with Cr/SS/GS; and grade IV, 50-75% of glomeruli with Cr/
SS/GS; grade V, >75% of glomeruli with Cr/SS/GS. The
immunofluorescence staining was graded: 0, 1+, 2+, and 3+.
RESULTS
The clinical characteristics at the time of the renal biopsies
are shown in Table 1. The 12 patients consisted of three males
and nine females, and the mean age at the time of diagnosis
was 48±18 yr. All patients complained of generalized edema,
which developed acutely over two weeks (range, 1-8). The
mean weight gain was 4.0 kg (% of body weight, 7.1%).
Hypertension was present in four patients (33%); two patients
had been diagnosed with hypertension before the renal biop-
sy, and the others were diagnosed at the time of the renal
biopsy. Hematuria (either microscopic or macroscopic) was
detected in 11 patients (91.7%), two of whom had episodes
of ‘‘synpharyngitic’’ gross hematuria before the renal biopsy.
The mean urinary protein excretion was 10.2±4.4 g/day.
Two patients (16.7%) had renal insufficiency (serum creati-
nine greater than 1.6 mg/dL) at presentation. The mean (±
SD) levels of serum albumin, serum cholesterol and serum
IgA were 2.2±0.6 g/dL, 394±104 mg/dL and 285±66
mg/dL, respectively. The serum IgA level was elevated (greater
than 400 mg/dL) in only one patient.  


































1 42 F Generalized 2.0 9.0, 16.1% Absent Microscopic 10.4 1.4 1.9 460 239 185
edema
2 39 M Generalized 2.0 1.0, 1.5% Absent Microscopic 9.0 0.9 2.7 374 NA 111
edema
3 19 M Generalized 1.5 0.0, 0.0% Present Macroscopic 8.8 1.7 3.1 258 228 NA
edema
4 30 F Generalized 2.0 5.0, 11.6% Absent Microscopic 7.8 0.7 1.8 529 198 107
edema
5 34 F Generalized 1.5 3.0, 7.1% Absent Absent 11.1 0.7 1.7 559 285 130
edema
6 64 F Generalized 1.0 0.0, 0.0% Absent Macroscopic 4.6 1.4 2.9 287 286 168
edema
7 46 M Generalized 8.0 0.0, 0.0% Present Microscopic 4.0 1.1 3.0 237 204 NA
edema
8 62 F Generalized 2.0 3.0, 4.6% Present Microscopic 20.1 1.1 2.1 418 270 138
edema
9 76 F Generalized 1.0 6.0, 10.0% Absent Microscopic 11.8 1.2 1.5 480 401 154
edema
10 57 F Generalized 2.0 4.0, 6.7% Present Microscopic 14.5 1.2 1.8 328 341 170
edema
11 34 F Generalized 4.0 12.0, 17.9% Absent Microscopic 7.3 1.3 2.0 377 359 168
edema
12 67 F Generalized 2.0 5.0, 10.0% Absent Microscopic 13.2 2.0 1.3 417 327 148
edema
Table 1. Clinical characteristics of responders at presentation
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All patients had a renal biopsy at the nephrotic stage. One
patient (patient 1) had already been diagnosed with IgAN
on renal biopsy five years previously; due to the development
of generalized edema and heavy proteinuria recently, a sec-
ond renal biopsy was performed. The second biopsy showed
‘‘diffuse foot process effacement’’ in addition to the typical
features of IgAN. The other 11 patients did not have a prior
renal biopsy. The light microscopic, immunofluorescence
and electron microscopic (EM) findings of the renal biopsy
are shown in Table 2. The distribution of the glomerular
grades of the 12 patients was: grade I, three (25%); grade
II, five (42%); and grade III, four (33%). Grade IV and V
IgAN was not reported among the 12 patients. There were
various degrees of mesangial proliferation and abnormality.
In all cases, the immunofluorescence demonstrated diffuse,
granular deposition of IgA in the glomerular mesangium.
Less intense fluorescence for IgG, IgM, C3, and fibrinogen
were sometimes detected. There were electron dense deposits
within the matrix of the mesangium and paramesangium.
Subendothelial deposits (patient 8) and mesangial interposi-
tion (patient 7), were occasionally demonstrated. Extensive
effacement and fusion of the visceral epithelial foot process-
es were detected in 8 patients (patient 4, 5, 6, 8, 9, 10, 11,
and 12), while focal effacement of the foot processes were
demonstrated in the remaining four patients. The glomeru-
lar basement membrane exhibited localized irregularities:
thinning, lamellation and duplication (patient 3, 4, and 10).
The patients received oral prednisolone (0.5-1.0 mg/kg/
day) after the renal biopsy. High-dose steroid was maintained
for 4 weeks, and then it was slowly tapered. All 12 patients
showed complete remission with steroid therapy. The response
to the steroids was prompt; the median time to response (pro-
teinuria of less than 1.0 g/day) was two months (range, 0-6),
and the median time to complete remission (proteinuria of
less than 0.3 g/day) was two months (range, 0-41). During
the tapering of the steroids, six patients received other immuno-
suppressant; cyclosporine (3 patients), cyclophosphamide (2
patients) and azathioprine (1 patient). Patients generally tol-
erated the medications well with manageable side effects,
including transient hyperglycemia, insomnia and cushingoid
changes. There were no significant adverse events except one
case of acute pyelonephritis.
The median duration of follow-up was 30 (6-84) months.
Seven episodes of relapse were reported in five patients during
steroid tapering. Six episodes of relapse responded to the inc-
rease of dosage or re-administration of steroids, which resulted
in complete remission again. For responders, the median time
to remission was two weeks (range, 0-4). Only one patient did
not respond to steroid therapy; in this case mycophenolate
mofetil and cyclosporine were added to the steroid treatment.
At the last follow-up, the urine protein and serum creatinine
were 2.27 g/day and 1.1 mg/dL, respectively, in this patient.






1 IgAN, grade III IgA 2+, C3 1+ Heavy mesangial deposits
Focal marked foot process effacement
2 IgAN, grade II IgA 1+ Tiny mesangial deposits
Focal moderate foot process effacement
3 IgAN, grade III IgA 2+, C3 1+ Small amount of mesangial deposits, partly irregular inner contour of GBM
Focal marked foot process effacement
4 IgAN, grade II IgA 2+ Moderate amount of mesangial deposits, focally thickened GBM
Wide foot process effacement
5 IgAN, grade II IgA 1+, C3 +/- Small amount of mesangial deposits
Wide foot process effacement
6 IgAN, grade III IgA 2+, C3 1+ Small amount of mesangial deposits
with features of Wide foot process effacement
tubulointerstitial nephritis
7 IgAN, grade II IgA 3+, IgG 2+, Small amount of mesangial deposits, mesangial interposition
C3 +/-, Fbg 2+ Focal mild foot process effacement
8 IgAN, grade III IgA 3+, IgM 1+, IgG 2+,  Moderate mesangial deposits, small amount of subendothelial deposits
C3 2+, Fbg 2+ Wide foot process effacement
9 IgAN, grade I IgA 2+, C3 1+ Small amount of mesangial deposits
Wide foot process effacement
10 IgAN, grade II IgA 1+, IgM +/1, IgG +/-, Small amount of mesangial deposits, mild to moderate GBM abnormality
Fbg +/- Wide foot process effacement
11 IgAN, grade I IgA 1+ Tiny amount of mesangial deposits
Wide foot process effacement
12 IgAN, grade I IgA 1+ Small amount of mesangial deposits
Wide foot process effacement
Table 2. Light, immunofluorescent and electron microscopic findings of responders
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DISCUSSION
In this study, we evaluated IgAN associated with steroid-
responsive nephritic syndrome from both the clinical and
histopathological findings. It is possible that these patients
had IgAN and MCD simultaneously. The clinical and patho-
logical features of typical mesangial IgA deposits, mesangial
hypercellularity and the presence of hematuria were consis-
tent with IgAN. However, the features of wide foot process
effacement on EM, sudden onset of generalized edema with
weight gain, massive proteinuria, severe hypoalbuminemia,
and severe hypercholesterolemia were characteristics of MCD.
Rapid response to steroid therapy, steroid dependence and
relapse during steroid tapering in some cases also suggested
MCD. 
These findings are different from those reported by Lai et
al. (3), where eight patients with IgAN, presented with steroid-
responsive nephrotic syndrome. They suggested that the eight
patients might have a variant type of IgAN, on the basis of
the clinical and pathological features including: the response
to steroid treatment was not as prompt as generally observed
with MCD; a higher incidence of hypertension, hematuria
and azotemia was reported as compared with typical MCD
cases. However, our 12 cases showed rapid response to steroid
therapy; the median time to complete remission was only two
months. The incidence of hypertension, hematuria and azotemia
in our study was higher than that generally seen with MCD,
yet the azotemia returned to normal after steroid therapy in
all except one patient. Also, the mean age (48±18 yr) at
diagnosis in our cases was older than that of previous stud-
ies (1, 4, 9). The old age at presentation could explain the
higher incidence of azotemia and hypertension. 
Interestingly, one patient already had a renal biopsy before
the development of the nephrotic syndrome. The first renal
biopsy showed typical mesangial IgA staining with mild
mesangial proliferation, and the second biopsy, at the nephrot-
ic stage, showed wide foot process effacement in addition to
the features of IgAN. This case may represent IgAN com-
plicated by MCD rather than a variant clinical manifesta-
tion of IgAN. The concept of these two diseases occurring
simultaneously might be helpful for the management of
IgAN patients with the nephrotic syndrome. The patients
evaluated in this case series likely illustrated patients with
the nephrotic syndrome caused by MCD in patients with
Steroid-users




Age (yr) 47.5±17.5 38.9±13.8 43.9±17.6 0.427
Male:female 3:9 7:6 10:11 0.304*
Follow-up periods (months) 35.3±23.4  41.1±20.5 38.6±23.5 0.743
At presentation
Hypertension (no. of patients, %) 4 (33%) 8 (62%) 10 (48%) 0.370*
Generalized edema (no. of patients, %) 12 (100%) 7 (54%) 13 (62%) 0.025*
Symptom duration (months) 0.7±0.5 4.5±6.5 4.2±7.8 0.004
Weight gain (kg) 4.0±3.7 -0.3±1.4 1.4±2.6 0.001
Serum creatinine (mg/dL) 1.23±0.38 2.30±2.01 1.70±1.20 0.053
Serum albumin (mg/dL) 2.15±0.62 3.15±0.42 3.01±0.36 0.000
Serum cholesterol (g/dL) 394±104 231±84 257±55 0.000
Serum IgA (mg/dL) 285±66 418±153 356±112 0.057
Proteinuria (g/day) 10.2±4.4 4.7±0.6 6.5±2.6 0.001
At last follow-up
Serum creatinine (mg/dL) 1.03±0.19 4.21±4.18 4.87±4.60 0.000
Proteinuria (g/day) 0.3±0.6 1.7±1.0 2.4±2.8 0.001
RRT (no. of patients, %) 0 (0%) 5 (38%) 9 (43%) 0.028*
Histologic grade of IgAN
Grade I (no. of patients) 3 0 0 0.000�
Grade II (no. of patients) 5 0 3
Grade III (no. of patients) 4 2 3
Grade IV (no. of patients) 0 5 6
Grade V (no. of patients) 0 6 9
Degree of mesangial IgA deposit
1+ (no. of patients) 5 1 2 0.008�
2+ (no. of patients) 5 3 7
3+ (no. of patients) 2 9 12
Table 3. Comparison of the clinical and pathology features in responders, non-responders and non-users
Values are mean±standard deviation or number of patients. Differences between two groups were assessed by Kruskal-Wallis test, χ2-test (*) or lin-
ear by linear association test (
�
).
RRT, renal replacement therapy. 
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preexisting IgAN, diagnosed by renal biopsy previously or
not. In several cases of recurrent nephrotic syndrome (10),
sequential renal biopsies have been performed with the ini-
tial biopsy showing features of MCD, not of IgAN. Howev-
er, the renal biopsies obtained later, revealed features of IgAN:
mesangial IgA staining on immunofluorescence, mesangial
electron dense deposits on EM and/or mesangial hypercellu-
larity. These cases showed the sequential development of
MCD and IgAN during the course of steroid dependent/
resistant MCD. 
During the study period, 13 IgAN patients with the ne-
phrotic syndrome did not respond to steroid treatment despite
the same treatment protocol, and 23 IgAN patients did not
received steroid treatment. We compared these 13 non-res-
ponders and 21 non-users with responders (Two patients of
the non-users were excluded because of inadequate biopsy
specimen.) The clinical and pathological features of these
three groups are summarized in Table 3. At presentation,
the responders showed greater weight gain (responders vs.
non-responders; 4.0 vs. -0.3 kg; p=0.003 by post-hoc Mann-
Whitney U test with Bonferroni correction), more protein-
uria (10.2 vs. 4.7 g/day; p=0.003) and lower serum albumin
(2.15 vs. 3.15 g/dL; p<0.001) than non-reponders. The initial
serum creatinine was lower in the responders; however, this
finding was not statistically significant. At the last follow-up,
the responders had lower serum creatinine (1.03 vs. 4.21 mg/
dL; p=0.003) and lower proteinuria (0.3 vs. 1.7 g/day; p<
0.001). None of the responders progressed to end stage renal
disease. However, five (38%) non-responders required dialy-
sis or renal transplantation. The histological comparison of
the two groups showed that responders had lower histological
grades on light microscopy and slight mesangial IgA stain-
ing on immunofluorescence. Among non-responders wide
podocyte effacement was detected in 2 patients, and focal
effacement was detected in 6 patients. High histologic grad-
ing of non-responders might explain the non-reversible course
of disease despite of wide foot process effacement. The clini-
copathologic characteristics of non-responders and non-users
were similar. The initial proteinuria was lower in nonrespon-
ders than in non-user; however, it was not statistically sig-
nificant. 
The IgAN associated with the nephrotic syndrome could
be divided into two distinct subgroups; one characterized by
the sudden onset of the nephrotic syndrome, preserved renal
function, mild glomerular injury, and good response to steroid
therapy. The other characterized by a relatively insidious onset
of disease, renal dysfunction, a high incidence of hyperten-
sion, severe structural damage, and progression to end stage
renal disease (11). A long-term controlled trial showed that
steroid therapy was beneficial to selected patients with IgAN,
who presented with the nephrotic syndrome (12). Seven pati-
ents (40%) out of 17 patients in the steroid-treatment group
responded to the corticosteroids, six of these seven patients
had a mild glomerular abnormality (grade I), and three out
of the seven patients relapsed after the corticosteroid treat-
ment were discontinued. The results of this trial suggested
that a mild glomerular pathology might indicate a steroid
responsive IgAN presenting with the nephrotic syndrome.
The seven responders, especially the six early responders
might have had simultaneous MCD and IgAN. 
MCD and IgAN could occur in a patient with more ad-
vanced IgAN. Patient with grade 4/5 IgAN can have struc-
tural abnormalities of the glomerular basement membrane
with IgAN itself, and these patient’s clinical manifestations
or response to steroid therapy might not be distinctive. One
non-responder among our cases responded partially to the
steroid therapy; although the diagnosis was IgAN, grade V,
the proteinuria decreased to 1.5 g/day from 5.5 g/day with
steroid therapy. However, this patient progressed to end stage
renal disease with heavy proteinuria six years after the renal
biopsy.  
This study has several limitations. First, this study was a
retrospective study. Retrospective study could be insufficient
to include all relevant patients and to collect complete follow-
up data. However, we tried to include all consecutive patients
and the follow-up rate was good (100%). Moreover, the pati-
ents in our study are rare, thus, we think only retrospective
study is the only feasible design. Second, there was no pre-
determined indication and dosage of steroid therapy. Physi-
cians decided to use steroid treatment at his/her discretion,
based on the clinicopathologic features of individual patients.
However, the response was achieved all the patients except
one. Therefore, the individual difference in steroid therapy
would not affect outcome. Last, no patient had a renal biop-
sy after remission of nephrotic syndrome. Pathologic find-
ing after remission would reveal the relationship of IgAN
and MCD in a patient.
The results of this study suggest that a subgroup of IgAN
presenting with the nephrotic syndrome can achieve a com-
plete remission with steroid treatment, especially in patients
with low grade IgAN. The nephrotic syndrome was charac-
terized by the sudden onset of generalized edema, heavy pro-
teinuria, severe hypoalbuminemia, and relatively mild renal
pathology in contrast to IgAN with steroid-non-responsive
nephrotic syndrome. Moreover, diffuse foot process efface-
ment was detected in most cases. Consideration of the pos-
sible simultaneous occurrence of MCD and IgAN might
help clinicians with patient management and prognosis. 
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